fbpx

PubMed: Cancer Treatment: Preclinical & Clinical

PubMed: Cancer Treatment: Preclinical & Clinical

J Natl Cancer Inst Monogr. 2021 Nov 28;2021(58):107-113. doi: 10.1093/jncimonographs/lgab010.

ABSTRACT

The first evidence that cannabinoids may have in vitro and in vivo antineoplastic activity against tumor cell lines and animal tumor models was published in the Journal of the National Cancer Institute nearly 50 years ago. Cannabinoids appear to induce apoptosis in rodent brain tumors by way of direct interaction with the cannabinoid receptor. They may inhibit angiogenesis and tumor cell invasiveness. Despite preclinical findings, attempts to translate the benefits from bench to bedside have been limited. This session provides a review of the basic science supporting the use of cannabinoids in gliomas, paired with the first randomized clinical trial of a cannabis-based therapy for glioblastoma multiforme. Another preclinical presentation reports the effects of cannabinoids on triple-negative breast cancer cell lines and how cannabidiol may affect tumors. The session’s second human trial raises concerns about the use of botanical cannabis in patients with advanced cancer receiving immunotherapy suggesting inferior outcomes.

PMID:34850894 | DOI:10.1093/jncimonographs/lgab010

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34850894/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20211202055901&v=2.15.0 December 1, 2021 11:00 am

বাংলা简体中文繁體中文EnglishFrançaisDeutschहिन्दीItaliano日本語한국어मराठीPortuguêsਪੰਜਾਬੀРусскийEspañolSvenskaతెలుగుไทยTürkçeУкраїнськаTiếng Việt